Loading
Flagship-founded blood-test company launching RESOLVE, a multi-cancer detection test for people with symptoms who are waiting for a diagnosis.
RESOLVE targets the symptomatic diagnostic window rather than asymptomatic screening, with tissue-of-origin output; first products expected commercially in H2 2026 after a $100M raise (2025). PROCARES prospective validation ongoing; multiple AACR 2026 presentations on the Harbinger HX methylation platform.
Harbinger Health's blood test meant for the weeks between a doctor suspecting cancer and a diagnosis, pointing to where in the body a cancer may be; it is not offered as a screening test for well people.
Shares Positive predictive value (PPV), Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Positive predictive value (PPV), DNA methylation profiling, The hardest cancers are found late.
Shares DNA methylation profiling, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Positive predictive value (PPV), The hardest cancers are found late.
Shares DNA methylation profiling, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Positive predictive value (PPV), Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Positive predictive value (PPV), DNA methylation profiling, Multi-cancer early detection (MCED).
Shares DNA methylation profiling, Multi-cancer early detection (MCED), The hardest cancers are found late.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/